Pregabalin Capsule
Product Images NDC 70518-2745

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-2745). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin 100mg 70518 2745 01

This is a description of a medication called Pregabalin with a National Drug Code (NDC) of 70518-2745-01. The medication comes in a capsule form with a strength of 100 mg manufactured by Novadoz Pharmaceuticals LLC in New Jersey. The medication should be kept away from children and the package insert should be followed for directions of use. The medication should be stored at room temperature between 20-26°C (63-77°F) with limited excursions permitted between 15-30°C (59-86°F) as per USP. The medication was repackaged by RemedyRepack Inc., and it is available by prescription only.*

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin is a medication available in a capsule form manufactured by Novadoz Pharmaceuticals LLC. The National Drug Code (NDC) for this medication is 70518-2745-00. It comes in a quantity of 90 capsules and has a strength of 100mg. The expiration date and lot number are not available. It should be stored between 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F), and kept out of reach of children. The source NDC is 72205-0014-90. The package insert should be checked for further directions. It is RX only, and it has been repackaged by RemedyRepack Inc., in Indiana, PA.*

FDA Label Image

Equation (Pregabain Gault Equation)

FDA Label Image

Fig-01 (Pregabalin Figure 01)

The text provides statistical data related to the efficacy of Pregabalin in terms of pain improvement among patients. It shows the percentage of patients whose condition improved after taking different doses of Pregabalin and a placebo. Additionally, it displays the percentage of improvement in pain from baseline after taking Pregabalin.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

The given text shows a graph displaying the percentage of patients who improved with Pregabalin medication vs Placebo based on the percentage improvement in pain from the baseline. The horizontal axis displays the percentage of improvement, ranging from 10 to 100. The vertical axis represents the percentage of patients improved. There is no further information available to provide a detailed description.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This is a chart showing the percentage of patients whose pain improved while taking pregabalin at different doses compared to a placebo. The percentages range from about 70% to 90% improvement. The chart also shows the percentage improvement in pain from baseline.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

FDA Label Image

Fig-05 (Pregabalin Figure 05)

This appears to be a chart or graph displaying the percentage of patients who improved after taking either pregabalin (at doses of 50mg or 100mg three times a day) or a placebo. The chart also measures the percentage improvement in pain from the baseline in increments of 10%.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

This text seems to be a part of a research/study report. It includes responder rates (%) for different doses of a medication (ranging from 50mg/day to 600mg/day) compared to a placebo. In some cases, statistical significance is noted. The study is referred to as "Study E1" and "Study E3," and the medication is administered either twice a day (BID), three times a day (TID), or the frequency is not specified (T). However, the text is not clear enough to provide more detailed information.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

FDA Label Image

Fig-09 (Pregabalin Figure 09)

This is a graph displaying the percent improvement in pain from baseline. The x-axis shows the percent improvement ranging from 20 to 100 while the y-axis shows the different daily doses of Pregabalin and placebo used. The doses used were Pregabalin 600 mg, Pregabalin 450 mg, Pregabalin 300 mg and Placebo. The graph also shows that Pregabalin 600 mg daily dose had the highest percentage of patients who improved.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

This appears to be a graph displaying the estimated percentage of subjects without LIR (likely incomplete response) for different doses of Pregabalin versus Placebo over a period of 180 days. The graph shows the estimates for each time point from Day 80 to Day 180.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

This is a graph that illustrates the percent of subjects who showed improvement from baseline to week 12 in a study comparing the medication Pregabalin to a placebo. The y-axis displays the percentage of subjects improved, ranging from 0 to 100, and the x-axis displays percentage ranges from 0 to 100 in increments of 10. The graph shows that a higher percentage of subjects taking Pregabalin improved compared to those taking the placebo.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

This table displays the percentage of subjects who showed improvement after 16 weeks of treatment with Pregabalin and placebo. The percentages are grouped based on the level of improvement, ranging from more than 10% to more than 80%.*

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.